Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Erythrocyte Complement Receptor 1 and Alzheimer Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by CHU de Reims.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
CHU de Reims
ClinicalTrials.gov Identifier:
NCT01565434
First received: March 26, 2012
Last updated: March 27, 2012
Last verified: March 2012

March 26, 2012
March 27, 2012
February 2012
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01565434 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Erythrocyte Complement Receptor 1 and Alzheimer Disease
Not Provided

Main objective: investigate whether a functional polymorphism of CR1 (length, number of binding sites in C4b C3b, erythrocyte density, rate of soluble CR1 ...) so determined genetic or acquired, is a susceptibility factor for the disease Alzheimer's.

Not Provided
Interventional
Not Provided
Primary Purpose: Screening
Alzheimer Disease
Other: CR1 impact
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
Not Provided
Not Provided

Inclusion Criteria:

  • caucasians people with a Alzheimer dementia defined on DSMIV criteria for patients and without Alzheimer disease for control subjects

Exclusion Criteria:

  • diseases modifying CR1 physiology
Both
18 Years and older
Yes
Contact: Rachid MAHMOUDI, MD rmahmoudi@chu-reims.fr
France
 
NCT01565434
REIMS-AOL2011-01
No
CHU de Reims
CHU de Reims
Not Provided
Not Provided
CHU de Reims
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP